ANDOVER, Mass. (AP) — ANDOVER, Mass. (AP) — TransMedics Group Inc. (TMDX) on Tuesday reported first-quarter earnings of $7.3 ...

TransMedics shares plummeted after the company posted first-quarter profit and revenue that missed Wall Street's forecast. Shares of the medical technology company fell 21% in after-hours trading on ...

Is TMDX a good stock to buy? We came across a bullish thesis on TransMedics Group, Inc. on Grillo Insights’s Substack by Eric García. In this article, we will summarize the bulls’ thesis on TMDX.

Management recently raised its sales outlook for 2025. TransMedics isn't the only company with a warm perfusion device for storing and transporting organs. From the end of 2024 through the opening ...

In its latest quarter, TransMedics reported solid gains in revenue and saw net income nearly triple from year-ago levels. TransMedics increased its full-year 2025 sales outlook. Co-founder/CEO Waleed ...

TransMedics Group unveiled its Controlled Hypothermic Organ Preservation System, or CHOPS, a new active cooling device for ...

TransMedics Group is leveraging its technological and logistical moat in organ transport, with OCS and NOP programs driving ...

United States-based medical technology company TransMedics has entered into a definitive agreement to invest in Germany-based ...

Shares of TransMedics Group (NASDAQ: TMDX) recently bounded higher in response to a first-quarter earnings report that was a lot better than investors were expecting. Downward revenue guidance ...

TransMedics reported second-quarter financial results that were considerably better than most investors had anticipated. On the sales front, gains of 38% to $157 million were healthily higher than ...

Here's our initial take on TransMedics' (NASDAQ: TMDX) second-quarter financial report. TransMedics reported second-quarter financial results that were considerably better than most investors had ...